{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:58:09Z","timestamp":1791619089092,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004754","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL139426"],"award-info":[{"award-number":["T32HL139426"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01 AG070329"],"award-info":[{"award-number":["K01 AG070329"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>While apixaban has demonstrated advantages over alternative direct oral anticoagulants (DOACs) in some settings, its comparative safety and effectiveness in cancer-associated venous thromboembolism (VTE) remain uncertain. Current guidelines recommend DOACs as first-line treatment for cancer-associated VTE, though they do not recommend any specific DOAC over another. This study aimed to quantify the risk of recurrent VTE, major bleeding, and clinically relevant non-major bleeding among individuals with cancer-associated VTE treated with apixaban versus rivaroxaban.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>In this retrospective cohort study, we used data from Medicare fee-for-service (2016\u20132020) and MarketScan (2016\u20132022), two U.S. administrative claims databases covering publicly and commercially insured individuals. We included individuals aged \u226565 years (Medicare) or 18\u201364 years (MarketScan) with active cancer, defined as a cancer diagnosis within 6 months before an index VTE event, who newly initiated apixaban or rivaroxaban within 30 days of that event. The outcomes were (1) hospitalization for recurrent VTE; (2) hospitalization for major bleeding; and (3) hospitalization or outpatient visit for clinically relevant non-major bleeding events. Eligible individuals were followed for outcomes at 6 months (consistent with guideline recommendations) and during the entire follow-up period. We used inverse probability of treatment weighting to adjust for baseline differences, including demographics, comorbidities (e.g., prior bleed), VTE risk factors, cancer type and treatments, and medication use, and applied inverse probability of censoring weighting to account for differential loss to follow-up. We analyzed outcomes using adjusted Cox proportional hazards models, pooling estimates using an inverse variance-weighted fixed-effects model. The final cohort included 6,329 apixaban and 4,260 rivaroxaban users across both databases. At 6 months, apixaban was associated with similar risks of recurrent VTE (hazard ratio [HR] 0.66, 95% confidence interval [CI] [0.40, 1.11]; <jats:italic>p<\/jats:italic>-value\u2009=\u20090.11) and major bleeding (HR 0.95, 95% CI [0.73, 1.23]; <jats:italic>p<\/jats:italic>\u2009=\u20090.70), and a lower risk of clinically relevant non-major bleeding (HR 0.84, 95% CI [0.74, 0.96]; <jats:italic>p<\/jats:italic>\u2009=\u20090.009) compared to rivaroxaban. The same pattern persisted during the extended follow\u2011up. The main limitation is the observational design, which may leave residual confounding despite adjustments using inverse probability weighting.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In cancer-associated VTE, apixaban was associated with similar risks of recurrent VTE and major bleeding, and a lower risk of clinically relevant non-major bleeding compared with rivaroxaban. These findings suggest apixaban may be a favorable option for anticoagulation in cancer-associated VTE when minimizing bleeding risk is a priority.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004754","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:48:41Z","timestamp":1758908921000},"page":"e1004754","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7951-6267","authenticated-orcid":true,"given":"Jingjing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-6370","authenticated-orcid":true,"given":"Hemalkumar B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-9662","authenticated-orcid":true,"given":"Jodi B.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-2986","authenticated-orcid":true,"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"7","key":"pmed.1004754.ref001","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"GH Lyman","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"pmed.1004754.ref002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2004.05292.x","article-title":"Management of thrombosis in cancer: primary prevention and secondary prophylaxis","volume":"128","author":"AYY Lee","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"pmed.1004754.ref003","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"JI Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"pmed.1004754.ref004","doi-asserted-by":"crossref","first-page":"109184","DOI":"10.1016\/j.thromres.2024.109184","article-title":"Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: a secondary analysis of the CANVAS trial","volume":"244","author":"H Uno","year":"2024","journal-title":"Thromb Res"},{"issue":"16","key":"pmed.1004754.ref005","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"NS Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"pmed.1004754.ref006","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"19","author":"MB Streiff","year":"2024","journal-title":"J Natl Comprehen Cancer Net"},{"issue":"4","key":"pmed.1004754.ref007","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"MV Huisman","year":"2020","journal-title":"Europ Heart J"},{"issue":"6","key":"pmed.1004754.ref008","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"SM Stevens","year":"2021","journal-title":"Chest"},{"issue":"9","key":"pmed.1004754.ref009","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH","volume":"22","author":"S Carlin","year":"2024","journal-title":"J Thromb Haemost"},{"key":"pmed.1004754.ref010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2023.02.001","article-title":"Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer","volume":"224","author":"AD Dhamane","year":"2023","journal-title":"Thromb Res"},{"issue":"1","key":"pmed.1004754.ref011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis","volume":"6","author":"T Fujisaki","year":"2024","journal-title":"JACC CardioOncol"},{"key":"pmed.1004754.ref012","volume-title":"Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis. Mayo Clinic Proceedings","author":"HE Fuentes","year":"2019"},{"issue":"1","key":"pmed.1004754.ref013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11239-020-02151-2","article-title":"Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer","volume":"51","author":"H Ueyama","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"pmed.1004754.ref014","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/jth.15799","article-title":"Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: a cohort study","volume":"20","author":"T Fukasawa","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"pmed.1004754.ref015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"WE Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"key":"pmed.1004754.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2021.04.026","article-title":"Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism","volume-title":"Mayo Clinic Proceedings","author":"DE Houghton","year":"2021"},{"issue":"11","key":"pmed.1004754.ref017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1055\/a-2316-5269","article-title":"Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2","volume":"124","author":"D Sueta","year":"2024","journal-title":"Thromb Haemost"},{"issue":"03","key":"pmed.1004754.ref018","article-title":"Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding","volume":"7","author":"KS Caroti","year":"2023","journal-title":"TH Open"},{"key":"pmed.1004754.ref019","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"SM Langan","year":"2018","journal-title":"BMJ"},{"key":"pmed.1004754.ref020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pds.2341","article-title":"A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data","author":"L Tamariz","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"pmed.1004754.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2020.06.022","article-title":"Comparative effectiveness and safety of direct-acting oral anticoagulants and warfarin in patients with venous thromboembolism and active cancer: an observational analysis","volume":"42","author":"GK Dawwas","year":"2020","journal-title":"Clin Ther"},{"issue":"5","key":"pmed.1004754.ref022","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bjh.15857","article-title":"Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism","volume":"185","author":"PL Lutsey","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"pmed.1004754.ref023","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data","volume":"135","author":"KM Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"issue":"17","key":"pmed.1004754.ref024","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"pmed.1004754.ref025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis","volume":"121","author":"A Cohen","year":"2021","journal-title":"Thromb Haemost"},{"issue":"12","key":"pmed.1004754.ref026","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study","volume":"55","author":"MC Fang","year":"2017","journal-title":"Med Care"},{"key":"pmed.1004754.ref027","unstructured":"Tamariz L, Harkins T, Nair V. Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data venous thromboembolism report. Mini-Sentinel website August. 2011;11."},{"issue":"7","key":"pmed.1004754.ref028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/pds.4783","article-title":"Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries","volume":"28","author":"N Shehab","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pmed.1004754.ref029","article-title":"Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days","author":"X Pan","year":"2014","journal-title":"Eur Heart J"},{"key":"pmed.1004754.ref030","article-title":"Persistence with dabigatran therapy for stroke prevention in patients with non-valvular atrial fibrillation: the Gloria-AF Registry","author":"C Teutsch","year":"2016","journal-title":"Am Soc Hematol"},{"issue":"5","key":"pmed.1004754.ref031","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/pds.5204","article-title":"Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data","volume":"30","author":"J Beyrer","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pmed.1004754.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/S0049-3848(14)50006-0","article-title":"Risk stratification strategies for cancer-associated thrombosis: an update","volume":"133","author":"AA Khorana","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"pmed.1004754.ref033","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism","volume":"117","author":"FA Klok","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"pmed.1004754.ref034","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/rth2.12214","article-title":"Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism","volume":"3","author":"FA Klok","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"30","key":"pmed.1004754.ref035","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"PC Austin","year":"2016","journal-title":"Stat Med"},{"issue":"28","key":"pmed.1004754.ref036","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"PC Austin","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"pmed.1004754.ref037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2167696815621645","article-title":"A primer on inverse probability of treatment weighting and marginal structural models","volume":"4","author":"F Thoemmes","year":"2016","journal-title":"Emerg Adulthood"},{"issue":"2","key":"pmed.1004754.ref038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"S Xu","year":"2010","journal-title":"Value Health"},{"issue":"25","key":"pmed.1004754.ref039","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"PC Austin","year":"2009","journal-title":"Stat Med"},{"issue":"5","key":"pmed.1004754.ref040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"MA Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"issue":"1","key":"pmed.1004754.ref041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"NC Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"issue":"3","key":"pmed.1004754.ref042","article-title":"Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study","volume":"7","author":"EH Kang","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"446","key":"pmed.1004754.ref043","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"JP Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"pmed.1004754.ref044","unstructured":"ClinicalTrials.gov (NCT03266783). Comparison of bleeding risk between rivaroxaban and apixaban for the treatment of acute venous thromboembolism (COBRRA); 2025 [updated 04 Apr 2025; cited 21 July 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03266783"},{"key":"pmed.1004754.ref045","unstructured":"Castellucci et al. [Online abstract, ISTH 2025 late-breaking session LB01.1] Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism: the COBRRA trial (NCT03266783) Washington, DC: ISTH 2025 Online Congress Program; 2025 [updated 22 Jun 2025; cited 30 July 2025]. Available from: https:\/\/s2.goeshow.com\/isth\/annual\/2025\/conference_program_sessions.cfm?session_key=F88226C9-B4DE-F006-7F2A-B1630DF8A3FA&session_date=Sunday,%20Jun%2022,%202025"},{"issue":"1","key":"pmed.1004754.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"W Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"pmed.1004754.ref047","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"pmed.1004754.ref048","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators EINSTEIN","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004754.ref049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/fcp.12091","article-title":"Pharmacology and mechanisms of action of new oral anticoagulants","volume":"29","author":"J-E Salem","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"22","key":"pmed.1004754.ref050","doi-asserted-by":"crossref","first-page":"13955","DOI":"10.3390\/ijms232213955","article-title":"Gastrointestinal bleeding due to NOACs use: exploring the molecular mechanisms","volume":"23","author":"A Saviano","year":"2022","journal-title":"Int J Molecul Sci"},{"issue":"3","key":"pmed.1004754.ref051","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"B Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"key":"pmed.1004754.ref052","doi-asserted-by":"crossref","first-page":"103074","DOI":"10.1016\/j.critrevonc.2020.103074","article-title":"Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: a systematic review and meta-analysis","volume":"154","author":"M Camilli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7424","key":"pmed.1004754.ref053","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/bmj.327.7424.1162","article-title":"Communicating risks at the population level: application of population impact numbers","volume":"327","author":"RF Heller","year":"2003","journal-title":"BMJ"},{"issue":"14","key":"pmed.1004754.ref054","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"I Mah\u00e9","year":"2025","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004754","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:43:50Z","timestamp":1759513430000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004754"}},"subtitle":[],"editor":[{"given":"Suzanne C.","family":"Cannegieter,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004754","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004754","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}